The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76%after MATILDE ...The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76%after MATILDE and 83%after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low-to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG]-score). Myelosuppression was the dose-limiting toxicity, with 9.5%of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 ±7%) was obtained.展开更多
文摘The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76%after MATILDE and 83%after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low-to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG]-score). Myelosuppression was the dose-limiting toxicity, with 9.5%of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 ±7%) was obtained.
